United States

People: Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$-0.11 (-0.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Delaney, Brendan 

Mr. Brendan Delaney is Chief Commercial Officer of the Company. Mr. Brendan was most recently Vice President, U.S. Commercial Hematology Oncology at Celgene. In this role, Brendan oversaw a team of roughly 400 professionals across sales, marketing and strategic alliances. Notably, under Brendan's leadership, the revenue for the group grew to over $7 billion annually, representing a significant proportion of Celgene's global revenue. Prior to this role, Brendan held a series of other senior-level marketing roles at Celgene. Before coming to Celgene he was at Novartis for five years, serving in a number of U.S. and global marketing roles within the Company's oncology business unit. Over the course of his 22-year commercial career Brendan has been involved in the launch of nine new oncology products and indications.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --